Ablation of glucagon receptor signaling by peptide-based glucagon antagonists improves glucose tolerance in high fat fed mice

Peptides

Volumn 60, Issue , 2014, Pages 95-101

  McShane, Laura M ^a   Franklin, Zara J ^a   O'Harte, Finbarr P M ^a   Irwin, Nigel ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

Diabetes; Glucagon antagonist; Glucose tolerance; Insulin sensitivity

Indexed keywords

CHOLESTEROL; DESHISTIDYLPROLYLGLUTAMIC ACID GLUCAGON; DESHISTIDYLPROLYLGLUTAMYL(LYSYL PAL)GLUCAGON; FAT; GLUCAGON; GLUCAGON DERIVATIVE; GLUCAGON RECEPTOR; GLUCAGON RECEPTOR ANTAGONIST; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HORMONE RECEPTOR BLOCKING AGENT; INSULIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEPTIDE DERIVATIVE; PEPTIDE;

ANIMAL EXPERIMENT; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FAT INTAKE; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; GLUCOSE TOLERANCE TEST; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LIPID DIET; MALE; MEDIATOR; MOUSE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PANCREAS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL MODEL; ANIMAL TISSUE; DRUG RECEPTOR BINDING; INSULIN RESISTANCE; ADVERSE EFFECTS; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; INBRED MOUSE STRAIN; INTRAPERITONEAL DRUG ADMINISTRATION; METABOLISM; STRUCTURE ACTIVITY RELATION; TIME;

ANIMALS; DIET, HIGH-FAT; GLUCAGON; GLUCOSE TOLERANCE TEST; INJECTIONS, INTRAPERITONEAL; MALE; MICE; MICE, INBRED STRAINS; PEPTIDES; RECEPTORS, GLUCAGON; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; TIME FACTORS;

EID: 84906831104     PISSN: 01969781     EISSN: 18735169     Source Type: Journal    
DOI: 10.1016/j.peptides.2014.08.002     Document Type: Article

References (42)

1. B. Ahrén, and A.J. Scheurink Marked hyperleptinemia after high-fat diet associated with severe glucose intolerance in mice Eur J Endocrinol 139 1998 461 467 (Pubitemid 28494094)
2. B. Ahrén The future of incretin-based therapy: novel avenues-novel targets Diabetes Obes Metab 13 2011 158 166
3. C.L. Brand, B. Rolin, P.N. Jørgensen, I. Svendsen, J.S. Kristensen, and J.J. Holst Immunoneutralization of endogenous glucagon with monoclonal glucagon antibody normalizes hyperglycaemia in moderately streptozotocin-diabetic rats Diabetologia 37 1994 985 993 (Pubitemid 24300455)
4. S. Cernea, and I. Raz Therapy in the early stage: incretins Diabetes Care 34 2011 264 271
5. J.W. Day, N. Ottaway, J.T. Patterson, V. Gelfanov, D. Smiley, and J. Gidda et al. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents Nat Chem Biol 5 2009 749 757
6. D. Demong, X. Dai, J. Hwa, M. Miller, S.I. Lin, and L. Kang et al. The discovery of N-((2H-tetrazol-5-yl)methyl)-4-((R)-1-((5r, 8R)-8-(tert-butyl)-3- (3,5-dichlorophenyl)-2-oxo-1,4-diazaspiro(4.5)dec-3-en-1-yl)-4,4-dimethylpentyl) benzamide (SCH 900822): a potent and selective glucagon receptor antagonist J Med Chem 57 2014 2601 2610
7. D.J. Drucker, S.I. Sherman, F.S. Gorelick, R.M. Bergenstal, R.S. Sherwin, and J.B. Buse Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits Diabetes Care 33 2010 428 433
8. P.R. Flatt, and C.J. Bailey Abnormal plasma glucose and insulin responses in heterozygous lean (ob/+) mice Diabetologia 20 1981 573 577 (Pubitemid 11096955)
9. Z.J. Franklin, F.P.M. O'Harte, and N. Irwin Effects of short-term chemical ablation of glucagon signalling by peptide-based glucagon receptor antagonists on insulin secretion and glucose homeostasis in mice Biol Chem 395 2014 433 442
10. N. Geary, H.R. Kissileff, F.X. Pi-Sunyer, and V. Hinton Individual, but not simultaneous, glucagon and cholecystokinin infusions inhibit feeding in men Am J Physiol 262 1992 975 980
11. R.W. Gelling, X.Q. Du, D.S. Dichmann, J. Romer, H. Huang, and L. Cui et al. Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice Proc Natl Acad Sci U S A 100 2003 1438 1443 (Pubitemid 36184020)
12. J. Gromada, I. Franklin, and C.B. Wollheim Alpha-cells of the endocrine pancreas: 35 years of research but the enigma remains Endocr Rev 28 2007 84 116 (Pubitemid 46220851)
13. W. Gu, H. Yan, K.A. Winters, R. Komorowski, S. Vonderfecht, and L. Atangan et al. Long-term inhibition of the glucagon receptor with a monoclonal antibody in mice causes sustained improvement in glycemic control, with reversible alpha-cell hyperplasia and hyperglucagonemia J Pharmacol Exp Ther 331 2009 871 881
14. K.M. Habegger, K.M. Heppner, N. Geary, T.J. Bartness, R. DiMarchi, and M.H. Tschöp The metabolic actions of glucagon revisited Nat Rev Endocrinol 6 2010 689 697
15. F.B. Hu Globalization of diabetes: the role of diet, lifestyle, and genes Diabetes Care 34 2011 1249 1257
16. 30PAL)-glucagon: long-acting peptide-based PEGylated and acylated glucagon receptor antagonists with potential antidiabetic activity Eur J Pharmacol 709 2013 43 51
17. F.K. Knop, K. Aaboe, T. Vilsbøll, A. Vølund, J.J. Holst, and T. Krarup et al. Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity Diabetes Obes Metab 14 2012 500 510
18. A.J. Krentz, and C.J. Bailey Oral antidiabetic agents: current role in type 2 diabetes mellitus Drugs 65 2005 385 411 (Pubitemid 40227460)
19. E.C. Lee, M. Tu, B.D. Stevens, J. Bian, G. Aspnes, and C. Perreault et al. Identification of a novel conformationally constrained glucagon receptor antagonist Bioorg Med Chem Lett 24 2014 839 844
20. Y. Liang, M.C. Osborne, B.P. Monia, S. Bhanot, W.A. Gaarde, and C. Reed et al. Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice Diabetes 53 2004 410 417 (Pubitemid 38174557)
21. C. Longuet, E.M. Sinclair, A. Maida, L.L. Baggio, M. Maziarz, and M.J. Charron et al. The glucagon receptor is required for the adaptive metabolic response to fasting Cell Metab 8 2008 359 371
22. T. Madsen, E.B. Schmidt, and J.H. Christensen The effect of n-3 fatty acids on C-reactive protein levels in patients with chronic renal failure J Renal Nutr 17 2007 258 263 (Pubitemid 46936230)
23. N. Mazzola Review of current and emerging therapies in type 2 diabetes mellitus Am J Manag Care 18 2012 17 26
24. I.A. Montgomery, N. Irwin, and P.R. Flatt Active immunization against (Pro3)GIP improves metabolic status in high-fat-fed mice Diabetes Obes Metab 12 2010 744 751
25. J. Mu, G. Jiang, E. Brady, Q. Dallas-Yang, F. Liu, and J. Woods et al. Chronic treatment with a glucagon receptor antagonist lowers glucose and moderately raises circulating glucagon and glucagon-like peptide 1 without severe alpha cell hypertrophy in diet-induced obese mice Diabetologia 54 2011 2381 2391
26. F.P.M. O'Harte, Z.J. Franklin, E.P. Rafferty, and N. Irwin Characterisation of structurally modified analogues of glucagon as potential glucagon receptor antagonists Mol Cell Endocrinol 381 2013 26 34
27. J.C. Parker, K.M. Andrews, M.R. Allen, J.L. Stock, and J.D. McNeish Glycemic control in mice with targeted disruption of the glucagon receptor gene Biochem Biophys Res Commun 290 2002 839 843 (Pubitemid 34687519)
28. A. Perea, F. Clemente, J. Martinell, M.L. Villanueva-Peñacarrillo, and I. Valverde Physiological effect of glucagon in human isolated adipocytes Horm Metab Res 27 1995 372 375
29. A.L. Peters Clinical relevance of non-HDL cholesterol in patients with diabetes Clin Diabetes 26 2009 3 7 (Pubitemid 351186100)
30. B. Raju, and P.E. Cryer Maintenance of the postabsorptive plasma glucose concentration: insulin or insulin plus glucagon? Am J Physiol Endocrinol Metab 289 2005 181 186
31. N. Rani, N. Vasudeva, and S.K. Sharma Quality assessment and anti-obesity activity of Stellaria media (Linn.) Vill BMC Complement Altern Med 12 2012 145
32. M.H. Shanik, Y. Xu, J. Skrha, R. Dankner, Y. Zick, and J. Roth Insulin resistance and hyperinsulinemia: is hyperinsulinemia the cart or the horse? Diabetes Care 31 2008 262 268
33. K.W. Sloop, J.X. Cao, A.M. Siesky, H.Y. Zhang, D.M. Bodenmiller, and A.L. Cox et al. Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors J Clin Invest 113 2004 1571 1581 (Pubitemid 39071680)
34. R.S. Surwit, M.N. Feinglos, J. Rodin, A. Sutherland, A.E. Petro, and E.C. Opara et al. Differential effects of fat and sucrose on the development of obesity and diabetes in C57BL/6J and A/J mice Metabolism 44 1995 645 651
35. R. Unger, and L. Orci The essential role of glucagon in the pathogenesis of diabetes mellitus Lancet 305 1975 14 16
36. A. Vater, S. Sell, P. Kaczmarek, C. Maasch, K. Buchner, and E. Pruszynska-Oszmalek et al. A mixed mirror-image DNA/RNA aptamer inhibits glucagon and acutely improves glucose tolerance in models of type 1 and type 2 diabetes J Biol Chem 288 2013 21136 21147
37. P.M. Vuguin, and M.J. Charron Novel insight into glucagon receptor action: lessons from knockout and transgenic mouse models Diabetes Obes Metab 13 2011 144 150
38. D.B. West, C.N. Boozer, D.L. Moody, and R.L. Atkinson Dietary obesity in nine inbred mouse strains Am J Physiol 262 1992 1025 1032
39. C. Weyer, P.A. Tataranni, C. Bogardus, and R.E. Pratley Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development Diabetes Care 24 2001 89 94
40. M.S. Winzell, C.L. Brand, N. Wierup, U.G. Sidelmann, F. Sundler, and E. Nishimura et al. Glucagon receptor antagonism improves islet function in mice with insulin resistance induced by a high-fat diet Diabetologia 50 2007 1453 1462 (Pubitemid 46879005)
41. S.C. Woods, T.A. Lutz, N. Geary, and W. Langhans Pancreatic signals controlling food intake; insulin, glucagon and amylin Philos Trans R Soc B: Biol Sci 361 2006 1219 1235 (Pubitemid 44882937)
42. H. Yan, W. Gu, J. Yang, V. Bi, Y. Shen, and E. Lee et al. Fully human monoclonal antibodies antagonizing the glucagon receptor improve glucose homeostasis in mice and monkeys J Pharmacol Exp Ther 32 2009 102 111